Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genscript BiotechSTU:G51 +0.57%72 Net Current Asset Value is €0.07 as of Dec. 2025, which is 100% below its 10-year median of 18.77. GuruFocus rates STU:G51 with a GF Score™ of 72/100 and a GF Value™ of €2.28 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 940 Biotechnology companies, Genscript Biotech ranks worse than 88.62% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Genscript Biotech's net current asset value per share for the quarter that ended in Dec. 2025 was €0.07.
The historical rank and industry rank for Genscript Biotech's Net Current Asset Value or its related term are showing as below:
STU:G51'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 4.51 Med: 18.77 Max: 88.5
Current: 25
During the past 12 years, the highest Price-to-Net-Current-Asset-Value Ratio of Genscript Biotech was 88.50. The lowest was 4.51. And the median was 18.77.
STU:G51's Price-to-Net-Current-Asset-Value is ranked worse than 88.62% of 940
companies
in the Biotechnology industry
Industry Median: 4.725
vs STU:G51: 25.00
Genscript Biotech (STU:G51) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Genscript Biotech Net Current Asset Value Related Terms
Genscript Biotech Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Genscript Biotech's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:G51 vs VRTX, REGN, ALNY: Net Current Asset Value Comparison
For the Biotechnology subindustry, Genscript Biotech's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genscript Biotech Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genscript Biotech's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Genscript Biotech's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of €0.07 mean?
Genscript Biotech (STU:G51) has a Net Current Asset Value of €0.07 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Genscript Biotech and its competitors. This is 100% below median its historical median of 18.77. Over the past decade, Genscript Biotech's Net Current Asset Value has ranged from 4.51 to 88.50. According to the industry distribution chart, Genscript Biotech ranks #833 out of 940 companies in the Biotechnology industry, placing it in the top 88.6%.
Is Genscript Biotech's Net Current Asset Value too high?
Genscript Biotech's current Net Current Asset Value of €0.07 is 100% below median its 10-year median of 18.77. Over the past 10 years, this metric has ranged from a low of 4.51 to a high of 88.50. Based on the distribution chart, Genscript Biotech ranks #833 out of 940 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Genscript Biotech has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genscript Biotech's Net Current Asset Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genscript Biotech ranks #833 out of 940 companies for Net Current Asset Value. This places Genscript Biotech in the lower half of its industry. The industry median Net Current Asset Value is 4.73. Historically, Genscript Biotech's own Net Current Asset Value has ranged from 4.51 to 88.50 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.73, based on 940 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Genscript Biotech and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genscript Biotech's current Net Current Asset Value is €0.07, which is 100% below median its own 10-year median of 18.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genscript Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genscript Biotech (STU:G51) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.28, compared to a current price of €1.75 — trading 23.2% below its estimated fair value. The current Net Current Asset Value is €0.07, which is 100% below median its 10-year median of 18.77. Genscript Biotech's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Genscript Biotech (STU:G51), the current Net Current Asset Value is €0.07 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genscript Biotech (STU:G51) Overvalued in 2026?
Based on GuruFocus' analysis, Genscript Biotech stock appears to be undervalued.
The current stock price of €1.75 is trading 23.2% below its estimated GF Value™ of €2.28.
GuruFocus considers Genscript Biotech to be Modestly Undervalued.
Key valuation signals for STU:G51:
Net Current Asset Value: €0.07 (100% below median its 10-year median of 18.77)
GF Value™: €2.28 vs. price of €1.75 (23.2% below fair value)
No single metric tells the full story. See the STU:G51 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GenScript Biotech Corp is an investment holding company engaged in the manufacture and sale of life science research products and services, including life science services and products, biologics development services, and industrial synthetic biology products. Its segments include life science services and products, which generate maximum revenue and provide research services and products; biologics development services, which support the development of therapeutic antibodies and CGT products; industrial synthetic biology, which provides enzyme development and production using engineered microbial strains; and the operation unit, which provides shared services. It operates in Mainland China, which generates maximum revenue, U.S., Europe, and the Asia Pacific excluding Mainland China.
72GF Score
Get the complete analysis for STU:G51
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:G51 has been successfully added to your 
